(1553093) Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon

Primary Author; Presenting Author(s)

• 

  Thomas E. Lew, MBBS BMedSci(Hons)

  Haematology trainee
  Peter MacCallum Cancer Centre and Royal Melbourne Hospital
  Melbourne, Victoria, Australia

  Slides

Co-Author(s)

• RB

  Rory Bennett, MBChB

  Department of Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Australia
• 

  Victor S. Lin, MBBS

  Basic physician trainee
  Royal Melbourne Hospital
  Parkville, Australia
• AW

  Ashley Whitechurch, RN

  Low grade lymphoma clinical nurse consultant
  Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Australia
• SH

  Sasanka M. Handunnetti, MBBS, PhD

  Consultant Haematologist
  Princess Alexandra Hospital, Australia
• PM

  Paula Marlton, MBBS

  Consultant Haemtologist
  Princess Alexandra Hospital, Australia
• YS

  Yandong Shen, PhD

  CLL research fellow
  Royal North Shore Hospital, New South Wales, Australia
• SM

  Stephen Mulligan, MBBS, PhD

  Consultant haematologist
  Royal North Shore Hospital
  Sydney, Australia
• JC

  Joshua Casan, MBBS, PhD

  Consultant Haematologist
  Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Australia
• Pb

  Piers blombery, MBBS, PhD

  Consultant Haematologist
  Peter MacCallum Cancer Centre, Australia
• CT

  Constantine S. Tam, MD, MBBS

  Consultant Haematologist
  Alfred Hospital and Monash University
  Melbourne, Victoria, Australia
• 

  Andrew W. Roberts, MBBS, PhD

  Metcalf Chair of Leukaemia Research
  Royal Melbourne Hospital & Peter MacCallum Cancer Centre
  Melbourne, Australia
• 

  John F. Seymour, MBBS, FRACP, PhD

  Director of Department of Haematology
  Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne
  Melbourne, Victoria, Australia
• 

  Philip Thompson, MBBS (Hons)

  Consultant Haematologist
  Department of Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre and The Sir Peter MaCallum Department of Clinical Oncology, University of Melbourne
  Melbourne, Victoria, Australia
• MA

  Mary Ann Anderson, MBBS, PhD

  Department of Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Australia